Trump's National Drug Strategy Embraces Treatment Access While Gutting Federal Support

The White House released its 195-page National Drug Control Strategy on May 4, 2026, outlining an ambitious vision for addressing America's ongoing addiction crisis. The document calls for making treatment more accessible than illicit drugs, preventing youth addiction, expanding recovery support, and reducing overdose deaths. Yet public health experts warn that these laudable goals stand in stark contradiction to the administration's own actions—mass layoffs of federal employees, cancellation of research grants, attacks on harm reduction organizations, and proposed cuts to Medicaid, the largest payer for addiction treatment nationwide.

A Strategy at Odds With Itself

The National Drug Control Strategy, published every two years as a congressional requirement, serves as the federal government's coordinated roadmap for addressing substance use disorders. This year's document emphasizes law enforcement approaches to reduce drug supply, with repeated references to a "war" against "foreign terrorist organizations"—the administration's terminology for drug cartels. It also outlines plans for artificial intelligence screening of imported drugs and nationwide wastewater testing to detect illegal substance use.

But the strategy's second half pivots to demand reduction through public health measures. It promotes expanded addiction treatment, prevention programs, and recovery support services. It acknowledges the role of overdose reversal medications like naloxone and calls for integrating faith-based approaches into recovery programs.

"Many components of the National Drug Control Strategy are things that we would agree with and that we fully support," said Libby Jones, who leads overdose prevention efforts at the Global Health Advocacy Incubator. "But there are disconnects in what the strategy says is important and then what they're actually going to fund. Those inconsistencies feel particularly loud in this strategy."

The Medicaid Paradox

Perhaps nowhere is this contradiction more apparent than in the administration's approach to Medicaid. The strategy repeatedly emphasizes increasing treatment access—at least half a dozen times mentioning the goal of making treatment easier to obtain than illegal drugs. Yet national data reveals the scope of the challenge: more than 80% of Americans who need substance use treatment don't receive it.

Medicaid serves as the primary source of healthcare coverage for adults with opioid use disorder, covering approximately 40% of all medication-assisted treatment nationwide. The strategy's treatment access goals would require strengthening this coverage. Instead, the administration's proposed Medicaid work requirements threaten to disenroll thousands of beneficiaries, while broader funding cuts to the program would reduce the very treatment capacity the strategy claims to support.

Yngvild Olsen, a national adviser with the Manatt Health consultancy who led substance use treatment policy at SAMHSA under the Biden administration, described the situation as creating "a sense of instability and uncertainty in the field." She left the agency approximately six months into Trump's second term.

The Whiplash Effect

The disconnect between strategy and implementation has created what advocates call a "whiplash" effect across the addiction services sector. In December 2025, Trump signed a reauthorization of the SUPPORT Act, which continues grants for treatment and recovery while maintaining Medicaid's requirement to cover all FDA-approved medications for opioid use disorder. In January 2026, he announced the Great American Recovery Initiative, including a $100 million investment to address homelessness, opioid addiction, and public safety.

Yet these announcements were followed by chaos. Approximately one month after the SUPPORT Act passed, billions of dollars in addiction-related grants were abruptly terminated—only to be reinstated within a frantic 24-hour period after public outcry. The president's FY2027 budget request proposes consolidating key federal agencies and cutting several addiction and mental health programs. Nearly 100 organizations in the field have signed a letter asking Congress to reject these proposals, as it did with similar requests last year.

Harm Reduction Under Fire

The strategy's treatment-focused rhetoric also conflicts with the administration's actions regarding harm reduction services. While the document acknowledges the importance of preventing overdose deaths, SAMHSA has issued guidance prohibiting federal grant funds for fentanyl test strips, xylazine test strips, sterile syringes, and overdose hotlines—dramatically reversing Biden administration policies.

This shift arrives as overdose deaths have declined 19% nationally since August 2023, gains that many public health experts attribute partly to expanded harm reduction infrastructure. The strategy's silence on these cuts—and its failure to address how treatment access can be expanded while simultaneously reducing support for the organizations that provide it—underscores the document's limited utility as an actual policy roadmap.

Racial Disparities Unaddressed

The strategy acknowledges that overdose death rates among Black Americans and Native Americans remain disproportionately high, and research suggests these disparities have widened even as overall mortality has declined. Yet the document offers few concrete proposals for addressing these inequities beyond general calls for expanded access.

Since 2000, more than 1.1 million people have died of drug overdoses in the United States. While recent declines offer hope, mortality remains elevated compared to earlier decades. The White House's Office of National Drug Control Policy called the strategy a "roadmap" that will "continue dismantling the drug supply and defeating the scourge of illicit drugs in our country."

Whether that roadmap leads anywhere meaningful may depend less on the document's aspirations and more on whether the administration's budget and policy decisions can be reconciled with its stated goals. For the millions of Americans struggling with substance use disorders—and the providers attempting to serve them—that reconciliation cannot come soon enough.